Cite
HARVARD Citation
Zielinski, C. et al. (n.d.). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet oncology. 17 (9), pp. 1230-1239. [Online].